{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:44:55Z","timestamp":1793054695053,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to quantify the burden of respiratory syncytial virus (RSV)- and influenza-attributed acute respiratory infections (ARI) in older adults in France. Modelling was applied to real-world data on ARI-attributed hospital admissions and in-hospital mortality to estimate pathogen-specific outcomes and investigate the underreporting of RSV in standard clinical practice. Additionally, healthcare resource utilisation was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, observational cohort study used routinely collected, secondary care data from the Programme National de M\u00e9dicalisation des Syst\u00e8mes d\u2019Information (PMSI) database. All patients aged\u2009\u2265\u200950\u00a0years with an ARI-related hospitalisation, identified through International Classification of Diseases, 10th Revision (ICD-10) coding, between July 2014 and February 2020 were included. The predicted number and annual rate of hospitalisations were calculated using a Quasi-Poisson regression model, stratified by age group. Sensitivity analyses were used to investigate cardiorespiratory hospital admissions and in-hospital mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>2,009,218 patients with an ARI-related hospitalisation were identified. Predicted rates of RSV- and influenza-attributable ARI hospitalisations ranged from 0.05 and 0.27 per 1000 person-years among 50\u201354-year-olds to 14.38 and 12.48 per 1000 person-years among\u2009\u2265\u200990-year-olds, respectively. Rates of in-hospital mortality were similar between the two pathogens, while RSV was predicted to account for a much larger number of cardiorespiratory hospitalisations than influenza. RSV-coded hospitalisations lasted 8\u201311\u00a0days across age groups, and 25.6% of 55\u201359-year-olds hospitalised with RSV were admitted to an intensive care unit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data reveal a substantial burden of RSV-related morbidity and mortality among older adults in France, demonstrating a need to prioritise RSV prevention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s15010-026-02799-7","type":"journal-article","created":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T07:48:57Z","timestamp":1780300137000},"page":"1825-1837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Respiratory syncytial virus in adults aged\u2009\u2265\u200950\u00a0years in France: a database and time-series modelling analysis (2014\u20132020)"],"prefix":"10.1007","volume":"54","author":[{"given":"Rachel M.","family":"Reeves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia","family":"Hagenaars","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Ammoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Borsik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jo\u00e3o","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triantafyllos","family":"Pliakas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Amodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin A.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Osei-Yeboah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alen","family":"Marijam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Loubet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,1]]},"reference":[{"issue":"10","key":"2799_CR1","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/S2213-2600(24)00255-8","volume":"12","author":"JG Wildenbeest","year":"2024","unstructured":"Wildenbeest JG, Lowe DM, Standing JF, Butler CC. Respiratory syncytial virus infections in adults: a narrative review. Lancet Respir Med. 2024;12(10):822\u201336. https:\/\/doi.org\/10.1016\/S2213-2600(24)00255-8.","journal-title":"Lancet Respir Med"},{"key":"2799_CR2","doi-asserted-by":"publisher","unstructured":"Nuttens C, Barbet V, Bignon-Favary C, et al. Estimation of general practitioner visits, hospitalizations and deaths attributable to Respiratory Syncytial Virus and Influenza Virus, and costs associated with hospitalizations, in older adults in France from 2010 to 2020. Open Forum Infect Dis. 2025;12(12):ofaf735. https:\/\/doi.org\/10.1093\/ofid\/ofaf735.","DOI":"10.1093\/ofid\/ofaf735"},{"issue":"1","key":"2799_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06399-8","volume":"21","author":"C Demont","year":"2021","unstructured":"Demont C, Petrica N, Bardoulat I, et al. Economic and disease burden of RSV-associated hospitalizations in young children in France, from 2010 through 2018. BMC Infect Dis. 2021;21(1):730. https:\/\/doi.org\/10.1186\/s12879-021-06399-8.","journal-title":"BMC Infect Dis"},{"issue":"Suppl 7","key":"2799_CR4","doi-asserted-by":"publisher","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","volume":"222","author":"T Shi","year":"2020","unstructured":"Shi T, Denouel A, Tietjen AK, et al. Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: a systematic review and meta-analysis. J Infect Dis. 2020;222(Suppl 7):S577\u201383. https:\/\/doi.org\/10.1093\/infdis\/jiz059.","journal-title":"J Infect Dis"},{"key":"2799_CR5","unstructured":"CDC. Respiratory syncytial virus infection (RSV): RSV in adults. 2025. Available at: https:\/\/www.cdc.gov\/rsv\/adults\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/rsv\/high-risk\/older-adults.html. Accessed Dec 2025."},{"key":"2799_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2023.105635","volume":"171","author":"P Loubet","year":"2024","unstructured":"Loubet P, Fernandes J, de Pouvourville G, et al. Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: a national hospital database study. J Clin Virol. 2024;171:105635. https:\/\/doi.org\/10.1016\/j.jcv.2023.105635.","journal-title":"J Clin Virol"},{"issue":"5","key":"2799_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/vaccines13050510","volume":"13","author":"F D'Ambrosio","year":"2025","unstructured":"D\u2019Ambrosio F, Lomazzi M, Moore M, et al. Addressing the underestimated burden of RSV in older adults in Europe: epidemiology, surveillance gaps, and public health implications. Vaccines (Basel). 2025;13(5):510. https:\/\/doi.org\/10.3390\/vaccines13050510.","journal-title":"Vaccines (Basel)."},{"issue":"9","key":"2799_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf528","volume":"12","author":"S Marot","year":"2025","unstructured":"Marot S, Demont C, Cocherie T, et al. Incidence and burden of respiratory syncytial virus-associated hospitalizations among people 65 and older in France: a national hospital database study. Open Forum Infect Dis. 2025;12(9):ofaf528. https:\/\/doi.org\/10.1093\/ofid\/ofaf528.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"2799_CR9","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s40266-015-0258-9","volume":"32","author":"AR Branche","year":"2015","unstructured":"Branche AR, Falsey AR. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging. 2015;32(4):261\u20139. https:\/\/doi.org\/10.1007\/s40266-015-0258-9.","journal-title":"Drugs Aging"},{"issue":"6","key":"2799_CR10","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/irv.12665","volume":"14","author":"W Cai","year":"2020","unstructured":"Cai W, Tolksdorf K, Hirve S, et al. Evaluation of using ICD-10 code data for respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020;14(6):630\u20137. https:\/\/doi.org\/10.1111\/irv.12665.","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"2799_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0244746","volume":"16","author":"MA Hamilton","year":"2021","unstructured":"Hamilton MA, Calzavara A, Emerson SD, et al. Validating International Classification of Disease 10th Revision algorithms for identifying influenza and respiratory syncytial virus hospitalizations. PLoS ONE. 2021;16(1):e0244746. https:\/\/doi.org\/10.1371\/journal.pone.0244746.","journal-title":"PLoS ONE"},{"issue":"1","key":"2799_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1017\/s095026880200729x","volume":"129","author":"B Muller-Pebody","year":"2002","unstructured":"Muller-Pebody B, Edmunds WJ, Zambon MC, Gay NJ, Crowcroft NS. Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995-March 1998. Epidemiol Infect. 2002;129(1):99\u2013106. https:\/\/doi.org\/10.1017\/s095026880200729x.","journal-title":"Epidemiol Infect"},{"key":"2799_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1218-z","volume":"15","author":"DM Fleming","year":"2015","unstructured":"Fleming DM, Taylor RJ, Lustig RL, et al. Modelling estimates of the burden of respiratory syncytial virus infection in adults and the elderly in the United Kingdom. BMC Infect Dis. 2015;15:443. https:\/\/doi.org\/10.1186\/s12879-015-1218-z.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"2799_CR14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/irv.12443","volume":"11","author":"RM Reeves","year":"2017","unstructured":"Reeves RM, Hardelid P, Gilbert R, Warburton F, Ellis J, Pebody RG. Estimating the burden of respiratory syncytial virus (RSV) on respiratory hospital admissions in children less than five years of age in England, 2007\u20132012. Influenza Other Respir Viruses. 2017;11(2):122\u20139. https:\/\/doi.org\/10.1111\/irv.12443.","journal-title":"Influenza Other Respir Viruses"},{"issue":"1","key":"2799_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-025-04249-x","volume":"23","author":"T Zhang","year":"2025","unstructured":"Zhang T, Reeves RM, Ma S, et al. Estimating the respiratory syncytial virus-associated hospitalisation burden in older adults in European countries: a systematic analysis. BMC Med. 2025;23(1):453. https:\/\/doi.org\/10.1186\/s12916-025-04249-x.","journal-title":"BMC Med"},{"key":"2799_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101227","volume":"51","author":"CK Johannesen","year":"2025","unstructured":"Johannesen CK, Gideonse D, Osei-Yeboah R, et al. Estimation of respiratory syncytial virus-associated hospital admissions in five European countries: a modelling study. Lancet Reg Health Eur. 2025;51:101227. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101227.","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"2799_CR17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/irv.12910","volume":"16","author":"A Sharp","year":"2022","unstructured":"Sharp A, Minaji M, Panagiotopoulos N, Reeves R, Charlett A, Pebody R. Estimating the burden of adult hospital admissions due to RSV and other respiratory pathogens in England. Influenza Other Respir Viruses. 2022;16(1):125\u201331. https:\/\/doi.org\/10.1111\/irv.12910.","journal-title":"Influenza Other Respir Viruses"},{"key":"2799_CR18","unstructured":"European Medicines Agency. Abrysvo (respiratory syncytial virus vaccine (bivalent, recombinant)). 2023. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/abrysvo-epar-medicine-overview_en.pdf. Accessed Sep 2025."},{"key":"2799_CR19","unstructured":"European Medicines Agency. Arexvy (Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)). 2023. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/arexvy-epar-medicine-overview_en.pdf. Accessed Sep 2025."},{"key":"2799_CR20","unstructured":"European Medicines Agency. mResvia (single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilised in the prefusion conformation). 2024. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/mresvia-epar-medicine-overview_en.pdf. Accessed Sep 2025."},{"issue":"6","key":"2799_CR21","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jamainternmed.2024.0212","volume":"184","author":"RC Woodruff","year":"2024","unstructured":"Woodruff RC, Melgar M, Pham H, et al. Acute cardiac events in hospitalized older adults with respiratory syncytial virus infection. JAMA Intern Med. 2024;184(6):602\u201311. https:\/\/doi.org\/10.1001\/jamainternmed.2024.0212.","journal-title":"JAMA Intern Med"},{"issue":"8","key":"2799_CR22","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1086\/605948","volume":"200","author":"CB Duncan","year":"2009","unstructured":"Duncan CB, Walsh EE, Peterson DR, Lee FE, Falsey AR. Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults. J Infect Dis. 2009;200(8):1242\u20136. https:\/\/doi.org\/10.1086\/605948.","journal-title":"J Infect Dis"},{"issue":"11","key":"2799_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad513","volume":"10","author":"A Njue","year":"2023","unstructured":"Njue A, Nuabor W, Lyall M, et al. Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries. Open Forum Infect Dis. 2023;10(11):ofad513. https:\/\/doi.org\/10.1093\/ofid\/ofad513.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"2799_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-025-01194-w","volume":"25","author":"Y Penders","year":"2025","unstructured":"Penders Y, Brusselle G, Falsey AR, et al. Burden of respiratory syncytial virus disease in adults with asthma and chronic obstructive pulmonary disease: a systematic literature review. Curr Allergy Asthma Rep. 2025;25(1):14. https:\/\/doi.org\/10.1007\/s11882-025-01194-w.","journal-title":"Curr Allergy Asthma Rep"},{"key":"2799_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/eurpub\/ckz186.643","author":"Y Le Strat","year":"2019","unstructured":"Le Strat Y, Caserio-Sch\u00f6nemann C, Bonaldi C, Guillet A, Lucas E. G\u00e9odes: the health indicators web portal of the French Public Health Agency. Eur J Public Health. 2019;29(Suppl 4). https:\/\/doi.org\/10.1093\/eurpub\/ckz186.643.","journal-title":"Eur J Public Health"},{"key":"2799_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5021","volume":"366","author":"HH Nam","year":"2019","unstructured":"Nam HH, Ison MG. Respiratory syncytial virus infection in adults. BMJ. 2019;366:l5021. https:\/\/doi.org\/10.1136\/bmj.l5021.","journal-title":"BMJ"},{"issue":"11","key":"2799_CR27","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/infdis\/jiad189","volume":"228","author":"R Osei-Yeboah","year":"2023","unstructured":"Osei-Yeboah R, Spreeuwenberg P, Del Riccio M, et al. Estimation of the number of respiratory syncytial virus-associated hospitalizations in adults in the European Union. J Infect Dis. 2023;228(11):1539\u201348. https:\/\/doi.org\/10.1093\/infdis\/jiad189.","journal-title":"J Infect Dis"},{"issue":"5","key":"2799_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/irv.70097","volume":"19","author":"C Liang","year":"2025","unstructured":"Liang C, Polkowska-Kramek A, Lade C, et al. Estimated incidence rate of specific types of cardiovascular and respiratory hospitalizations attributable to respiratory syncytial virus among adults in Germany between 2015 and 2019. Influenza Other Respir Viruses. 2025;19(5):e70097. https:\/\/doi.org\/10.1111\/irv.70097.","journal-title":"Influenza Other Respir Viruses"},{"issue":"3","key":"2799_CR29","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40121-024-00920-7","volume":"13","author":"M Haeberer","year":"2024","unstructured":"Haeberer M, Bruyndonckx R, Polkowska-Kramek A, et al. Estimated respiratory syncytial virus-related hospitalizations and deaths among children and adults in Spain, 2016-2019. Infect Dis Ther. 2024;13(3):463\u201380. https:\/\/doi.org\/10.1007\/s40121-024-00920-7.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"2799_CR30","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1111\/irv.13043","volume":"16","author":"AR Branche","year":"2022","unstructured":"Branche AR, Saiman L, Walsh EE, et al. Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults. Influenza Other Respir Viruses. 2022;16(6):1151\u201360. https:\/\/doi.org\/10.1111\/irv.13043.","journal-title":"Influenza Other Respir Viruses"},{"issue":"4","key":"2799_CR31","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/irv.12643","volume":"13","author":"H Schmidt","year":"2019","unstructured":"Schmidt H, Das A, Nam H, Yang A, Ison MG. Epidemiology and outcomes of hospitalized adults with respiratory syncytial virus: a 6-year retrospective study. Influenza Other Respir Viruses. 2019;13(4):331\u20138. https:\/\/doi.org\/10.1111\/irv.12643.","journal-title":"Influenza Other Respir Viruses"},{"issue":"7","key":"2799_CR32","doi-asserted-by":"publisher","first-page":"943 e1","DOI":"10.1016\/j.cmi.2023.03.003","volume":"29","author":"H Celante","year":"2023","unstructured":"Celante H, Oubaya N, Fourati S, et al. Prognosis of hospitalised adult patients with respiratory syncytial virus infection: a multicentre retrospective cohort study. Clin Microbiol Infect. 2023;29(7):943 e1-943 e8. https:\/\/doi.org\/10.1016\/j.cmi.2023.03.003.","journal-title":"Clin Microbiol Infect"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02799-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02799-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02799-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:10:20Z","timestamp":1786702220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02799-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["2799"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02799-7","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RMR, XC and AM: employees of, and hold financial equities in, GSK. SH, RA and BB: employees of IQVIA, which was paid by GSK to conduct the study. MJF: employee of, and holds financial equities in, GSK; received support for attending meetings and\/or travel from GSK as an employee. TP: contingent worker of GSK; has received grants or contracts from BioNTech, Impact Epilysis and UCB; consulting fees from BioNTech, GambleAware, International Centre for Research on Women, John Snow Inc, Pathfinder, UCB and UNAIDS. EA: has received consulting fees from MSD, Sanofi Pasteur and VIHTALI; payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing or educational events from GSK, Moderna, Pfizer and VIHTALI; has participated on a Data Safety Monitoring Board or Advisory Board for GSK, Moderna, MSD, Sanofi Pasteur and VIHTALI. CAR: has received consulting fees from GSK. RO-Y: has received grants or contracts from AstraZeneca. PL: has received consulting fees and support for attending meetings and\/or travel from AstraZeneca, GSK, Moderna, MSD, Pfizer, Seqirus and Sanofi Pasteur; has received payment or honoraria for lectures, presentations, speakers\u2019 bureaus, manuscript writing, or educational events from AstraZeneca, GSK, MSD, Moderna, Pfizer, Sanofi Pasteur and Seqirus.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research study was conducted retrospectively from data obtained for clinical purposes. The study complied with all applicable laws regarding subject privacy. No direct subject contact or primary collection of individual human subject data occurred. Study results are in tabular form and presented as aggregate analyses that omit subject identification, therefore informed consent, ethics committee or institutional review board approval was not required.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}